Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB.
about
Tumor promoting or tumor suppressing of NF-kB, a matter of cell context dependencyArsenite induces a cell stress-response gene, RTP801, through reactive oxygen species and transcription factors Elk-1 and CCAAT/enhancer-binding proteinInactivation of the CYLD deubiquitinase by HPV E6 mediates hypoxia-induced NF-kappaB activationLUBAC regulates NF-κB activation upon genotoxic stress by promoting linear ubiquitination of NEMOInduction of a pro-apoptotic ATM-NF-kappaB pathway and its repression by ATR in response to replication stressJFC1 is transcriptionally activated by nuclear factor-kappaB and up-regulated by tumour necrosis factor alpha in prostate carcinoma cellsNF-kappa B-mediated repression of growth arrest- and DNA-damage-inducible proteins 45alpha and gamma is essential for cancer cell survivalIdentification of a human NF-kappaB-activating protein, TAB3Morphoproteomic confirmation of an activated nuclear factor-кBp65 pathway in follicular thyroid carcinomaDifferential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphomaGrape seed proanthocyanidines and skin cancer prevention: inhibition of oxidative stress and protection of immune systemAstrocyte elevated gene-1: recent insights into a novel gene involved in tumor progression, metastasis and neurodegenerationTherapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancerThe proteosome inhibitor MG132 attenuates retinoic acid receptor trans-activation and enhances trans-repression of nuclear factor kappaB. Potential relevance to chemo-preventive interventions with retinoidsGene Therapy Applications to Cancer TreatmentExonuclease III protection assay with FRET probe for detecting DNA-binding proteinsMicroarray analysis of tumor necrosis factor alpha induced gene expression in U373 human glioblastoma cellsNew insights into the role of nuclear factor-kB in cell growth regulationWhen ubiquitin meets NF-κB: a trove for anti-cancer drug developmentNeuroendocrine differentiation and the ubiquitin-proteasome system in cancer: Partners or enemies?NF-κB in cellular senescence and cancer treatmentMultiple roles of toll-like receptor 4 in colorectal cancerReceptor activator of NF-κB ligand induces cell adhesion and integrin α2 expression via NF-κB in head and neck cancers.Hepatitis C Virus Stimulates the Expression of Cyclooxygenase-2 via Oxidative Stress: Role of Prostaglandin E2 in RNA ReplicationCrystal Structure of a Human I B Kinase Asymmetric DimerTranscription Factors in the Cellular Response to Charged Particle ExposureTo be an ally or an adversary in bladder cancer: the NF-κB story has not unfoldedmiR-221/222 targets adiponectin receptor 1 to promote the epithelial-to-mesenchymal transition in breast cancerStimulation of interferon regulatory factor-1 by prolactinIs there more to BARD1 than BRCA1?The non-genomic crosstalk between PPAR-gamma ligands and ERK1/2 in cancer cell linesThe c-Rel transcription factor and B-cell proliferation: a deal with the devilFeverfew: weeding out the root of leukaemiaNuclear factor kappaB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activityFisetin inhibits migration and invasion of human cervical cancer cells by down-regulating urokinase plasminogen activator expression through suppressing the p38 MAPK-dependent NF-κB signaling pathwayHydrogen sulfide-releasing naproxen suppresses colon cancer cell growth and inhibits NF-κB signalingInhibition of nickel nanoparticles-induced toxicity by epigallocatechin-3-gallate in JB6 cells may be through down-regulation of the MAPK signaling pathwaysNrf2 and NF-κB and Their Concerted Modulation in Cancer Pathogenesis and ProgressionAcquired resistance of human T cells to sulfasalazine: stability of the resistant phenotype and sensitivity to non-related DMARDsDevelopment of sulfasalazine resistance in human T cells induces expression of the multidrug resistance transporter ABCG2 (BCRP) and augmented production of TNFalpha
P2860
Q23912835-104A92F6-485E-4708-9D19-5CD57836A2D8Q23916954-18A4F4AD-A153-43E0-A42B-9F39B7CD184FQ24311308-323D8E0E-0A2A-4E4A-A350-10EF5AF13EF5Q24318791-361A3DAF-652B-4528-A6CD-86C9550BDFA8Q24336239-FB7804BD-6351-4B8F-96B6-98454A8583FEQ24534726-CE6C516A-87CF-48B1-8DB3-798254F0F54EQ24564706-3238AE5F-A653-4DCB-8742-FF50E4DD236AQ24621651-364AFA83-20E7-45A2-A920-E112F0F69A22Q24630133-4C0BD51E-48B2-40E9-8F13-35413C0723C0Q24643447-83F003E1-CC54-4AD8-A88C-2263CECBF908Q24656612-D1EAAB53-B16F-4895-9A9A-A59E4746A7A0Q24676501-7431A66A-9945-4898-9CCB-7D5F3930AB9AQ24681630-595FC82F-3BC2-488F-A15B-7052CA348B1FQ24792397-5669180C-FA72-4DA9-ABB9-8E9125106ED1Q24792808-91EF9AAB-2E2B-4B1F-AE89-3A71545A81C1Q24802809-88B8EEA4-83D2-4EFD-9FDE-6A438E408F0AQ24804694-05AB06AF-150B-4CDB-A490-5040FF10CC32Q26058119-E9271E97-1479-401C-B98C-15DD58ABC1EAQ26827754-2DDDB9C9-24BE-46B8-B4D3-12CAC47AD0FCQ26860284-D249151B-A2FC-4848-8595-6D8DD0C04D64Q27007045-505B5793-5F1B-49A6-B474-44CBD8CA30AAQ27008380-2B935E3C-EAAC-4DA7-AE49-5A9773946603Q27326719-CDF51921-0CEE-4118-8EEB-CD91147A1829Q27470314-1A86A536-3FE8-4E0F-90B6-3E6D6088A16FQ27678740-B245FA90-9CED-4D9D-803E-50B527399254Q28069717-9400B0B2-1E4D-4870-8DE2-6B4A302D99E6Q28086858-588949A5-AEB4-438A-A03A-E38843DEA28EQ28115315-BD997C1D-ECAC-4879-9123-04CD6C57D996Q28207550-62C7A42A-71E5-4D1B-A50B-C4AE09468A84Q28236135-CBC1981A-274B-4B41-BAFA-E4F0D834A3A3Q28238709-B5B687D5-D0BC-4B6A-86A5-EB0BB65A1C10Q28241767-58A39DFF-14B7-48D2-B332-2E85AD335BB0Q28268808-BAAD1C4E-852D-4057-87DE-FD3AA4028F68Q28383134-366900B2-0A70-4D21-A6A4-8926D60B7099Q28386841-25D5AC5B-D542-48C9-AD36-FDB65E205BE2Q28387183-17D09150-E26F-4847-AA65-F514491B99B4Q28388783-CF7112B5-8BA4-4AE7-A3D5-1115A4093955Q28391385-032FAD05-38A2-45DB-A617-1D31BF8748FDQ28394186-7BCE7A48-F15A-46D4-9C43-F8B15DC8DDFDQ28394197-1B7857B9-B96A-4D7F-AEB6-7CFEEE13B45A
P2860
Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Control of oncogenesis and can ...... ranscription factor NF-kappaB.
@ast
Control of oncogenesis and can ...... ranscription factor NF-kappaB.
@en
Control of oncogenesis and can ...... ranscription factor NF-kappaB.
@nl
type
label
Control of oncogenesis and can ...... ranscription factor NF-kappaB.
@ast
Control of oncogenesis and can ...... ranscription factor NF-kappaB.
@en
Control of oncogenesis and can ...... ranscription factor NF-kappaB.
@nl
prefLabel
Control of oncogenesis and can ...... ranscription factor NF-kappaB.
@ast
Control of oncogenesis and can ...... ranscription factor NF-kappaB.
@en
Control of oncogenesis and can ...... ranscription factor NF-kappaB.
@nl
P2860
P356
P1476
Control of oncogenesis and can ...... ranscription factor NF-kappaB.
@en
P2093
A S Baldwin
P2860
P304
P356
10.1172/JCI11991
P407
P577
2001-02-01T00:00:00Z